Furthermore, treating AML cell lines with the PKC inhibitor, enzastaurin, blocks the phosphorylation of PKCα and its downstream target, ERK, and also prevents PKCα membrane recruitment10. Here, MAPK1 is linked to acute myeloid leukemia.